Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Cross Above 50 Day Moving Average on Analyst Downgrade

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) shares passed above its 50 day moving average during trading on Monday after Wall Street Zen upgraded the stock from a sell rating to a hold rating. The stock has a 50 day moving average of $22.04 and traded as high as $23.75. Damora Therapeutics, Inc. Common Stock shares last traded at $22.50, with a volume of 1,232,736 shares changing hands.

A number of other equities analysts have also commented on the stock. Guggenheim assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Friday, November 6th. They set a “buy” rating and a $59.00 price target on the stock. TD Cowen upgraded Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday, August 24th. HC Wainwright reaffirmed a “buy” rating and set a $45.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Jefferies Financial Group initiated coverage on Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They set a “buy” rating and a $50.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, September 14th. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $46.38.

Read Our Latest Stock Analysis on Damora Therapeutics, Inc. Common Stock

Insider Transactions at Damora Therapeutics, Inc. Common Stock

In other Damora Therapeutics, Inc. Common Stock news, CEO Jennifer Jarrett bought 12,500 shares of the business’s stock in a transaction dated Friday, September 25th. The shares were purchased at an average price of $20.23 per share, for a total transaction of $252,875.00. Following the purchase, the chief executive officer directly owned 512,500 shares of the company’s stock, valued at approximately $10,367,875. This represents a 2.50% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bellevue Group AG increased its holdings in shares of Damora Therapeutics, Inc. Common Stock by 18.6% in the third quarter. Bellevue Group AG now owns 1,919,383 shares of the company’s stock worth $40,844,000 after purchasing an additional 300,537 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the second quarter worth $303,000. Arizona State Retirement System bought a new stake in Damora Therapeutics, Inc. Common Stock during the second quarter valued at $260,000. Seven Fleet Capital Management LP bought a new stake in Damora Therapeutics, Inc. Common Stock during the second quarter valued at $7,398,000. Finally, Braidwell LP bought a new stake in Damora Therapeutics, Inc. Common Stock during the second quarter valued at $42,146,000. Institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Stock Up 4.2%

The company has a 50-day moving average of $22.04 and a 200 day moving average of $25.60. The firm has a market capitalization of $1.39 billion, a PE ratio of -15.96 and a beta of 1.52.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.12. As a group, equities analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -2.09 EPS for the current fiscal year.

Damora Therapeutics, Inc. Common Stock Company Profile

(Get Free Report)

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.

Featured Stories

Receive News & Ratings for Damora Therapeutics Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Damora Therapeutics Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.